Quick Answer
Ensysce Biosciences, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $5.07 million for the year ending 2025.
- Ensysce Biosciences, Inc. showed a decrease of -2.8% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Ensysce Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $444.5 thousand | Q3 2021: $1.20 million | Q1 2022: $603.1 thousand | Q2 2022: $207.5 thousand | Q3 2022: $279.4 thousand | Q1 2023: $789.6 thousand | Q2 2023: $490.5 thousand | Q3 2023: $435.4 thousand | Q1 2024: $305.7 thousand | Q2 2024: $181.8 thousand | Q3 2024: $3.42 million | Q1 2025: $1.32 million | Q2 2025: $1.37 million | Q3 2025: $493.1 thousand.
- Over the full 5 years of available data (2021 to 2025), Ensysce Biosciences, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 43.5%.
- Historical annual values: Fiscal year 2025: $5.07 million | Fiscal year 2024: $5.21 million | Fiscal year 2023: $2.23 million | Fiscal year 2022: $2.52 million | Fiscal year 2021: $3.53 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: